The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review

Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study

(2015) Samantha A. Molsberry et al.   AIDS

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?

(2015) Jonathan Underwood et al.   AIDS

HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

(2015) Christina M Marra   ANTIVIRAL THERAPY

APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals – a cross-sectional observational study

(2015) Lucette A Cysique et al.   BMC Neurology

Defining Amyloid Pathology in Persons With and Without Dementia Syndromes

(2015) Roger N. Rosenberg   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Amyloid PET Positivity in Dementia Syndromes

(2015) Rik Ossenkoppele et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

(2015) J. Beardsley et al.   NEUROLOGY

Neurocognitive similarities between severe chronic schizophrenia and behavioural variant frontotemporal dementia

(2015) Hui-Minn Chan et al.   PSYCHIATRY RESEARCH

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

(2015) Francesca Ferretti et al.   Current HIV/AIDS Reports

Peripheral Blood Mononuclear Cells HIV DNA Levels Impact Intermittently on Neurocognition

(2015) Lucette A. Cysique et al.   PLoS One

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

(2014) Viktor Dahl et al.   AIDS

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility

(2014) Massimiliano Fabbiani et al.   ANTIVIRAL THERAPY

Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing

(2014) Jennifer H Barnett et al.   BMC Neurology

HIV-1 Tat C phosphorylates VE-cadherin complex and increases human brain microvascular endothelial cell permeability

(2014) Ritu Mishra et al.   BMC NEUROSCIENCE

Editorial Commentary: Protease Inhibitor Monotherapy: Safe for the CNS in Durably Suppressed Patients?

(2014) S. L. Letendre   CLINICAL INFECTIOUS DISEASES

Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control

(2014) Andrea Calcagno et al.   CLINICAL INFECTIOUS DISEASES

Editorial Commentary: Should Longitudinal Multisite Studies Become the New Standard for Investigating Neurocognitive Functions in HIV Infection?

(2014) L. A. Cysique   CLINICAL INFECTIOUS DISEASES

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

A Prospective Cohort Study of Neurocognitive Function in Aviremic HIV-Infected Patients Treated With 1 or 3 Antiretrovirals

(2014) I. Perez-Valero et al.   CLINICAL INFECTIOUS DISEASES

Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

(2014) R. K. Heaton et al.   CLINICAL INFECTIOUS DISEASES

Reducing central nervous system complications associated with the human immunodeficiency virus

(2014) D. Mclauchlan et al.   JOURNAL OF NEUROLOGY

HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research

(2014) Lucette A. Cysique et al.   JOURNAL OF NEUROVIROLOGY

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

(2014) José L. Casado et al.   JOURNAL OF NEUROVIROLOGY

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

(2014) Lishomwa C. Ndhlovu et al.   JOURNAL OF NEUROVIROLOGY

The relationship of CPE to HIV dementia: Slain by an ugly fact?

(2014) J. R. Berger et al.   NEUROLOGY

Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection

(2014) A. C. Young et al.   NEUROLOGY

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

(2014) E. C. Caniglia et al.   NEUROLOGY

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

(2014) I. Grant et al.   NEUROLOGY

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people

(2014) D. B. Clifford et al.   NEUROLOGY

Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

(2014) Lecia A. M. Brown et al.   PLoS One

A better alternative to stratified permuted block design for subject randomization in clinical trials

(2014) Wenle Zhao   STATISTICS IN MEDICINE

Psychosocial, mental health, and behavioral issues of aging with HIV

(2014) Sergio Rueda et al.   Current Opinion in HIV and AIDS

Evolving clinical phenotypes in HIV-associated neurocognitive disorders

(2014) Ned Sacktor et al.   Current Opinion in HIV and AIDS

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques

(2013) Kathleen M. Kelly et al.   AIDS

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

(2013) Matteo Vassallo et al.   AIDS

Randomized Trial of Central Nervous System–Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder

(2013) Ronald J. Ellis et al.   CLINICAL INFECTIOUS DISEASES

Dealing with Mild Cognitive Impairment

(2013) Donald L. Courtney   CLINICS IN GERIATRIC MEDICINE

Neuronal toxicity of efavirenz: a systematic review

(2013) Eric H Decloedt et al.   Expert Opinion On Drug Safety

An investigation of the effects of antiretroviral central nervous system penetration effectiveness on procedural learning in HIV+ drug users

(2013) Michael J. Wilson et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Global NeuroAIDS Roundtable

(2013) Jeymohan Joseph et al.   JOURNAL OF NEUROVIROLOGY

Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy

(2013) Assawin Gongvatana et al.   JOURNAL OF NEUROVIROLOGY

A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain 1H Magnetic Resonance Spectra

(2013) Caroline D. Rae   NEUROCHEMICAL RESEARCH

HIV, Vascular and Aging Injuries in the Brain of Clinically Stable HIV-Infected Adults: A 1H MRS Study

(2013) Lucette A. Cysique et al.   PLoS One

HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients

(2013) Victor G. Valcour et al.   PLoS One

Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study

(2013) José R. Santos et al.   PLoS One

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy

(2013) Ignacio Pérez-Valero et al.   PLoS One

The Neuropsychological Profile of Alzheimer Disease

(2013) S. Weintraub et al.   Cold Spring Harbor Perspectives in Medicine

Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers

(2012) Virawudh Soontornniyomkij et al.   AIDS

Defining Neurocognitive Impairment in HIV: Deficit Scores Versus Clinical Ratings

(2012) K. Blackstone et al.   CLINICAL NEUROPSYCHOLOGIST

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

(2012) Alexia Cusini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-infected persons with bipolar disorder are less aware of memory deficits than HIV-infected persons without bipolar disorder

(2012) Kaitlin Blackstone et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy

(2012) Torsak Bunupuradah et al.   JOURNAL OF NEUROVIROLOGY

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

(2012) Alan Winston et al.   NEURORADIOLOGY

Cognitive Dysfunction among HIV Positive and HIV Negative Patients with Psychosis in Uganda

(2012) Noeline Nakasujja et al.   PLoS One

The Four Seasons approach to the management of modern HIV medicine in high-income countries

(2012) Edwina J. Wright   Sexual Health

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

(2011) Jarek Harezlak et al.   AIDS

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

(2011) Lucette A Cysique et al.   BMC Neurology

Depression, Cognition, and Self-Appraisal of Functional Abilities in HIV: An Examination of Subjective Appraisal Versus Objective Performance

(2011) April D. Thames et al.   CLINICAL NEUROPSYCHOLOGIST

Neurocognitive Impact of Substance Use in HIV Infection

(2011) Desiree A Byrd et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

(2011) L. Garvey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change

(2011) Lucette A. Cysique et al.   JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY

Diagnosing Symptomatic HIV-Associated Neurocognitive Disorders: Self-Report Versus Performance-Based Assessment of Everyday Functioning

(2011) K. Blackstone et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

(2011) L. Garvey et al.   NEUROLOGY

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

(2011) Megan E. McPhail et al.   Current HIV/AIDS Reports

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

(2010) Giovanna Melica et al.   AIDS

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

(2010) Marlene Smurzynski et al.   AIDS

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

(2010) Ana Canestri et al.   CLINICAL INFECTIOUS DISEASES

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study

(2010) Rebekah L. Puls et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients

(2010) Juan Manuel Tiraboschi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 gp120-Induced Injury to the Blood-Brain Barrier: Role of Metalloproteinases 2 and 9 and Relationship to Oxidative Stress

(2010) Jean-Pierre Louboutin et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

(2010) Robert K. Heaton et al.   JOURNAL OF NEUROVIROLOGY

Neuropsychological Performance in Mainland China: The Effect of Urban/Rural Residence and Self-Reported Daily Academic Skill Use

(2010) Saurabh Gupta et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

(2009) Aylin Yilmaz et al.   AIDS

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

(2009) L. A. Cysique et al.   NEUROLOGY

HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: The SEARCH 001 Cohort Study

(2009) V. G. Valcour et al.   NEUROLOGY

Neuropsychological Functioning and Antiretroviral Treatment in HIV/AIDS: A Review

(2009) Lucette A. Cysique et al.   NEUROPSYCHOLOGY REVIEW

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

(2009) Aylin Yilmaz et al.   PLoS One

Diagnostic Labels, Stigma, and Participation in Research Related to Dementia and Mild Cognitive Impairment

(2009) Linda Garand et al.   Research in Gerontological Nursing

Neurodegeneration and Ageing in the HAART Era

(2008) Bruce J. Brew et al.   Journal of Neuroimmune Pharmacology